Understanding real-world treatment patterns and clinical outcomes in AL amyloidosis patients diagnosed in Canada: A population-based cohort study [0.03%]
了解在加拿大诊断的AL型淀粉样变性患者的真实世界治疗模式和临床结局:一项基于人群的队列研究
Victor H Jimenez-Zepeda,Donna Reece,Rodrigo Rigo et al.
Victor H Jimenez-Zepeda et al.
Amyloid light chain (AL) amyloidosis is a rare and chronic bone marrow disorder. Existing claims data can be used to help understand the real-world treatment patterns and outcomes of this patient population. Various population-based adminis...
Aggressive, early resistant and relapsed mantle cell lymphoma distinct extrinsic microenvironment highlighted by transcriptome analysis [0.03%]
转录组学分析强调了侵袭性、早期耐药和复发的套细胞淋巴瘤独特的外来微环境特征
Yannick Le Bris,Adeline Normand,Louise Bouard et al.
Yannick Le Bris et al.
Immunotherapy strategies relying on innate or adaptive immune components are increasingly used in onco-haematology. However, little is known about the infiltrated lymph nodes (LN) or bone marrow (BM) landscape of mantle cell lymphoma (MCL)....
Crystal-storing histiocytes and plasma cells, crystalline corneal deposits and atypical MRI lesions in multiple myeloma [0.03%]
多发性骨髓瘤患者的晶形细胞、晶形角膜沉着物及非典型MRI病灶
Muhammad Khakwani,Hayder Hussein,Guy Pratt et al.
Muhammad Khakwani et al.
Amirali Vahedi,Tahereh Madani,Behrooz Gharib et al.
Amirali Vahedi et al.
Jessica Sue Yi Wong,Shalal Sadullah
Jessica Sue Yi Wong
Case Reports
EJHaem. 2022 Sep 6;3(4):1365-1366. DOI:10.1002/jha2.367 2022
Diving in the big blue: Atypical Mott cells in rapidly fatal primary amyloidosis [0.03%]
在茫茫大海中潜水:致命性原发性淀粉样变中的非典型Mott细胞
Kenza Rwayane,Baptiste Le Calvez,Valentin Le Roch et al.
Kenza Rwayane et al.
COVID-19 systematic screening of asymptomatic haematopoietic stem cell donors: Less if often more [0.03%]
Covid-19无偿献血者系统筛查:少即是多
Lucie Blandin,Elise Tolmer,Eric Hermet et al.
Lucie Blandin et al.
From COVID pandemic spread until now, many HSCT unrelated donor registries recommend as a precaution a systematic COVID-19 testing for all donors during the precollection time. Literature is quite poor to support this systematic attitude. W...
Case Reports
EJHaem. 2022 Sep 15;3(4):1381-1384. DOI:10.1002/jha2.556 2022
Neutralizing monoclonal antibodies for early treatment of hospital-acquired SARS-CoV-2 infection in hematologic patients [0.03%]
中和单克隆抗体用于血液病患者的医院获得性新冠病毒感染早期治疗
Linda Bussini,Diletta Testi,Beatrice Tazza et al.
Linda Bussini et al.
Efficacy of early treatment with anti-SARS-CoV-2 spike protein monoclonal antibodies (mAbs) for nosocomial SARS-CoV-2 infection in hematologic patients is unknown. Retrospective, cohort study conducted in four Italian teaching hospitals. We...
Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID-19 vaccine: A single-center prospective observational study (NCT05074706) [0.03%]
血液系统肿瘤患者两剂BNT162b2新冠疫苗接种后体液及细胞免疫应答的单中心前瞻性观察研究(NCT05074706)
Elisa Bossi,Andrea Aroldi,Lorenza Maria Borin et al.
Elisa Bossi et al.
Hematological patients at higher risk of severe COVID-19 were excluded from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine trials. In this single-center observational prospective study (NCT05074706), we evaluate im...
Increased prescription rate of anti-infective agents after diagnosis of myelodysplastic syndromes [0.03%]
诊断骨髓增生异常综合征后抗感染药物处方率增加
Johanne Rozema,Mels Hoogendoorn,Iris Potma et al.
Johanne Rozema et al.
The a priori risk for infections in patients with myelodysplastic syndromes (MDS) is unknown. This study examines prescription rates of anti-infective agents in MDS patients before and after diagnosis, in both in- and outpatient settings, t...